Federal Register / Vol. 74, No. 80 / Tuesday, April 28, 2009 / Notices 19231 

general nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and an 

indication of the approximate time requested 

to make their presentation on or before May 

6, 2009. Time allotted for each presentation 

may be limited. If the number of registrants 

requesting to speak is greater than can be 

reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by May 7, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact AnnMarie 

Williams, Conference Management Staff, at 

240–276–8932, at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/oc/ 

advisory/default.htm for procedures on 

public conduct during advisory committee 

meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: April 22, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–9642 Filed 4–27–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Science Board to the Food and Drug 

Administration; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Science Board to the 

Food and Drug Administration (Science 

Board). 

General Function of the Committee: The 

Science Board provides advice primarily to 

the Commissioner of Food and Drugs and 

other appropriate officials on specific 

complex and technical issues, as well as 

emerging issues within the scientific 

community in industry and academia. 

Additionally, the Science Board provides 

advice to the agency on keeping pace with 

technical and scientific evolutions in the 

fields of regulatory science, on formulating 

an appropriate research agenda, and on 

upgrading its scientific and research facilities 

to keep pace with these changes. It will also 

provide the means for critical review of 

agency sponsored intramural and extramural 

scientific research programs. 

Date and Time: The meeting will be held 

on Monday, May 18, 2009, from 9 a.m. to 3 

p.m. 

Addresses: Hilton Washington DC/ 

Rockville Hilton, 1750 Rockville Pike, 

Rockville, MD 20852. 

Contact Person: Carlos Pen ̃ a, Office of the 

Commissioner, Food and Drug 

Administration (HF–33), 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–6687, or FDA 

Advisory Committee Information Line, 1– 

800–741–8138 (301–443–0572 in the 

Washington, DC area), code 3014512603. 

Please call the Information Line for up-todate information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly enough 

to provide timely notice. Therefore, you 

should always check the agency’s Web site 

and call the appropriate advisory committee 

hot line/phone line to learn about possible 

modifications before coming to the meeting. 

Agenda: The Science Board will hear about 

and discuss updates from the following 

subcommittees: (1) The review of each 

Center’s projects within scientific priority 

areas, (2) the review of research at the Center 

for Veterinary Medicine, and (3) the review 

of FDA’s scientific information technology 

infrastructure modernization initiatives. The 

Science Board will also hear updates on 

rapid detection of Salmonella in foods and 

the handling of biospecimens used for 

genomic and proteomic analyses. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 

material will be made publicly available at 

the location of the advisory committee 

meeting, and the background material will be 

posted on FDA’s Web site after the meeting. 

Background material is available at http:// 

www.fda.gov/ohrms/dockets/ac/acmenu.htm, 

click on the year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before May 

11, 2009. Oral presentations from the public 

will be scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify the 

contact person and submit a brief statement 

of the general nature of the evidence or 

arguments they wish to present, the names 

and addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation on or 

before May 7, 2009. Time allotted for each 

presentation may be limited. If the number of 

registrants requesting to speak is greater than 

can be reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by May 8, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact Dr. Carlos 

Pen ̃ a at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/oc/ 

advisory/default.htm for procedures on 

public conduct during advisory committee 

meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: April 22, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–9643 Filed 4–27–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Neurological Devices Panel of the 

Medical Devices Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Neurological Devices 

Panel of the Medical Devices Advisory 

Committee. 

General Function of the Committee: To 

provide advice and recommendations to the 

agency on FDA’s regulatory issues. 

Date and Time: The meeting will be held 

on May 14, 2009, from 8 a.m. to 5 p.m. 

Location: Holiday Inn, Ballroom, Two 

Montgomery Village Ave., Gaithersburg, MD. 

Contact Person: Peter L. Hudson, Center for 

Devices and Radiological Health, (HFZ–410), 

Food and Drug Administration, 9200 

Corporate Blvd., Rockville, MD 20850, 240– 

276–3737, or FDA Advisory Committee 

Information Line, 1–800–741–8138 (301– 

443–0572 in the Washington, DC area), code 

3014512513. Please call the Information Line 

for up-to-date information on this meeting. A 


erowe on PROD1PC64 with NOTICES
19232 Federal Register / Vol. 74, No. 80 / Tuesday, April 28, 2009 / Notices 

notice in the Federal Register about last 

minute modifications that impact a 

previously announced advisory committee 

meeting cannot always be published quickly 

enough to provide timely notice. Therefore, 

you should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn about 

possible modifications before coming to the 

meeting. 

Agenda: The committee will discuss, make 

recommendations and vote on a premarket 

approval application for the DuraSeal XactTM

Sealant System, sponsored by Confluent 

Surgical Inc. This device is indicated for use 

as an adjunct to sutured dural repair to 

obtain watertight closure during spinal 

surgery. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 

material will be made publicly available at 

the location of the advisory committee 

meeting, and the background material will be 

posted on FDA’s Web site after the meeting. 

Background material is available at http:// 

www.fda.gov/ohrms/dockets/ac/acmenu.htm, 

click on the year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before April 

30, 2009. Oral presentations from the public 

will be scheduled for 30 minutes at the 

beginning of the committee deliberations and 

for 30 minutes near the end of the 

deliberations. Those desiring to make formal 

oral presentations should notify the contact 

person and submit a brief statement of the 

general nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and an 

indication of the approximate time requested 

to make their presentation on or before April 

28, 2009. Time allotted for each presentation 

may be limited. If the number of registrants 

requesting to speak is greater than can be 

reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by April 29, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact Ms. 

AnnMarie Williams, Conference Management 

Staff, at 240–276–8932, at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/oc/ 

advisory/default.htm for procedures on 

public conduct during advisory committee 

meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: April 22, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–9641 Filed 4–27–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Statement of Organization, Functions 

and Delegation of Authority 

Notice is hereby given that I delegate 

to the Director of the Office of Refugee 

Resettlement the following authority 

delegated to the Assistant Secretary for 

Children and Families by the Secretary 

of the Department of Health and Human 

Services (HHS) under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008, 

Public Law 110–457, section 235. 

(a) Authority Delegated 

1. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(a)(1) to work in conjunction 

with the Secretary of Homeland 

Security, the Secretary of State, and the 

Attorney General, to develop policies 

and procedures to ensure that 

unaccompanied alien children (UAC) 

are safely repatriated to their country of 

nationality or of last habitual residence. 

2. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(a)(5)(A) to work in 

conjunction with the Secretary of State 

and the Secretary of Homeland Security, 

nongovernmental organizations, and 

other national and international 

agencies and experts, to create a pilot 

program to develop and implement best 

practices for the repatriation and 

reintegration of UAC. 

3. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(b)(1) to provide care and 

custody of all UAC, except as otherwise 

provided under section 235(a), 

including responsibility for their 

detention, where appropriate. 

4. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(b)(4) to develop age 

determination procedures in 

consultation with the Secretary of 

Homeland Security. 

5. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(c)(1) to establish policies 

and programs to ensure that UAC are 

protected from traffickers and other 

persons seeking to victimize or 

otherwise engage such children in 

criminal, harmful or exploitative 

activity. 

6. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(c)(2) to place an 

unaccompanied alien child in the least 

restrictive setting that is in the best 

interest of the child. In making such 

placements, personnel in the 

Administration for Children and 

Families may consider danger to self, 

danger to the community, and risk of 

flight. Concerning placements in a 

secure facility, the personnel in the 

Administration for Children and 

Families shall review the placements, at 

a minimum, on a monthly basis to 

determine if such placements remain 

warranted. Placement of child 

trafficking victims may include 

placement in an Unaccompanied 

Refugee Minor (URM) program, 

pursuant to section 412(d) of the 

Immigration and Nationality Act (8 

U.S.C. 1522(d)). 

7. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(c)(3)(A) to place an 

unaccompanied alien child with a 

custodian upon determining that the 

proposed custodian is capable of 

providing for the child’s physical and 

mental well-being. Such determination 

shall, at a minimum, include 

verification of the custodian’s identity 

and relationship to the child and an 

independent finding that the custodian 

has not engaged in any activity that 

would pose a potential risk to the child. 

8. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(c)(3)(B) to conduct a home 

study for a child who is a victim of a 

severe form of trafficking in persons, a 

special needs child with a disability, a 

child who has been a victim of physical 

or sexual abuse under circumstances 

that indicate that the child’s health or 

welfare has been significantly harmed or 

threatened, or a child whose proposed 

sponsor clearly presents a risk of abuse, 

maltreatment, exploitation, or 

trafficking to the child based on all 

available objective evidence. 

9. Authority under the William 

Wilberforce Trafficking Victims 

Protection Reauthorization Act of 2008 

section 235(c)(3)(B) to conduct followVerDate Nov<24>2008 15:33 Apr 27, 2009 Jkt 217001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\28APN1.SGM 28APN1

erowe on PROD1PC64 with NOTICES